Shenghui Tang

Follow

Generating author description...

All published works
Action Title Year Authors
+ Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials” 2023 Yuan-Li Shen
Sirisha L. Mushti
Flora Mulkey
Thomas Gwise
Xin Wang
Jiaxi Zhou
Xin Gao
Shenghui Tang
Marc R. Theoret
Richard Pazdur
+ Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021 2022 Sundeep Agrawal
Shaily Arora
Laleh Amiri‐Kordestani
R. Angelo de Claro
Lola A. Fashoyin-Aje
Nicole Gormley
Tamy Kim
Steven J. Lemery
Gautam U. Mehta
Emma C. Scott
+ Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients 2022 Jeanne Fourie Zirkelbach
Mirat Shah
Jonathon Vallejo
Joyce Cheng
Amal Ayyoub
Jiang Liu
Rachel Hudson
Rajeshwari Sridhara
Gwynn Ison
Laleh Amiri‐Kordestani
+ Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials 2022 Mallorie H. Fiero
Jessica Roydhouse
Vishal Bhatnagar
Ting‐Yu Chen
Bellinda L. King‐Kallimanis
Shenghui Tang
Paul G. Kluetz
+ PDF Chat External control arms in oncology: current use and future directions 2022 Pallavi S. Mishra‐Kalyani
L. Amiri Kordestani
Donna R. Rivera
Harpreet Singh
Amna Ibrahim
R. Angelo DeClaro
Yuan Li Shen
Shenghui Tang
R. Sridhara
Paul G. Kluetz
+ Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials 2021 Yuan-Li Shen
Xin Wang
Mushti Sirisha
Flora Mulkey
Jiaxi Zhou
Xin Gao
Lijun Zhang
Thomas Gwise
Shenghui Tang
Marc R. Theoret
+ PDF Chat Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples 2021 Anup Amatya
Mallorie H. Fiero
Erik Bloomquist
A. K. Sinha
Steven J. Lemery
Harpreet Singh
Amna Ibrahim
Martha Donoghue
Lola A. Fashoyin-Aje
R. Angelo de Claro
+ An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast Cancer 2019 Erik Bloomquist
Susan Jin
Jiaxi Zhou
Shenghui Tang
Rajeshwari Sridhara
+ Current Statistical Challenges in Oncology Clinical Trials in the Era of Targeted Therapy 2015 Rajeshwari Sridhara
Kun He
Lei Nie
Yuan-Li Shen
Shenghui Tang
+ Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study 2013 Lijun Zhang
Chia‐Wen Ko
Shenghui Tang
Rajeshwari Sridhara
+ Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis 2012 Jenny J. Zhang
Huanyu Chen
Kun He
Shenghui Tang
Robert Justice
Patricia Keegan
Richard Pazdur
Rajeshwari Sridhara
+ PDF Chat Overestimation of the Effect Size in Group Sequential Trials 2012 Jenny J. Zhang
Gideon M. Blumenthal
Kun He
Shenghui Tang
Patricia Cortazar
Rajeshwari Sridhara
Common Coauthors
Commonly Cited References
Action Title Year Authors # of times referenced
+ Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios” 2020 Ray Lin
Ji Lin
Satrajit Roychoudhury
Keaven M. Anderson
Tianle Hu
Bo Huang
Larry Leon
Jason J. Z. Liao
Rong Liu
Xiaodong Luo
2
+ PDF Chat Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis? 2019 Boris Freidlin
Edward L. Korn
2
+ PDF Chat Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience 2014 Suzanne E. Dahlberg
Geoffrey I. Shapiro
Jeffrey W. Clark
Bruce E. Johnson
2
+ The Drug-Dosing Conundrum in Oncology — When Less Is More 2021 Mirat Shah
Atiqur Rahman
Marc R. Theoret
Richard Pazdur
2
+ The Strong Null Hypothesis and the MaxCombo Test: Comment on “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance form a Cross-Pharma Working Group.” 2021 Dominic Magirr
Carl‐Fredrik Burman
2
+ PDF Chat Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group 2021 Satrajit Roychoudhury
Keaven M. Anderson
Jiabu Ye
Pralay Mukhopadhyay
2
+ Proportional hazards tests and diagnostics based on weighted residuals 1994 Patricia M. Grambsch
Terry M. Therneau
2
+ PDF Chat Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? 2009 Sophie Postel‐Vinay
H-T Arkenau
David Olmos
Joo Ern Ang
Jorge Barriuso
Sue Ashley
Udai Banerji
Johann S. de Bono
Ian Judson
S.B. Kaye
1
+ Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials? 2011 Francesco Pignatti
Rob Hemmings
Bertil Jönsson
1
+ Bias and Trials Stopped Early for Benefit 2010 Steven N. Goodman
Donald A. Berry
Janet Wittes
1
+ PDF Chat Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies 2011 Edward L. Korn
Boris Freidlin
Jeffrey S. Abrams
1
+ On the bias of maximum likelihood estimation following a sequential test 1986 John Whitehead
1
+ Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012 2014 Leonard Sacks
Hala Shamsuddin
Yuliya Yasinskaya
Khaled Bouri
Michael Lanthier
Rachel E. Sherman
1
+ Estimating and reducing bias in group sequential designs with Gaussian independent increment structure 1997 José C. Pinheiro
David L. DeMets
1
+ PDF Chat Adaptive adjustment of the randomization ratio using historical control data 2013 Brian P. Hobbs
Bradley P. Carlin
Daniel J. Sargent
1
+ Partial residuals for the proportional hazards regression model 1982 David Schoenfeld
1
+ PDF Chat Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials 2013 Scott Berry
Kristine Broglio
Susan Groshen
Donald A. Berry
1
+ Ethical concerns about adaptive randomization 2015 Colin B. Begg
1
+ Redefining the primary objective of phase I oncology trials 2014 Mark J. Ratain
1
+ Marginal Structural Models and Causal Inference in Epidemiology 2000 James M. Robins
Miguel A. HernĂĄn
Babette Brumback
1
+ PDF Chat Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis 2014 Hajime Uno
Brian Claggett
LĂŒ Tian
Eisuke Inoue
Paul Gallo
Toshio Miyata
Deborah Schrag
Masahiro Takeuchi
Yoshiaki Uyama
Lihui Zhao
1
+ Practical and statistical issues in missing data for longitudinal patient-reported outcomes 2013 Melanie L. Bell
Diane L. Fairclough
1
+ Measurement error in the timing of events: effect on survival analyses in randomized clinical trials 2010 Edward L. Korn
Lori E. Dodd
Boris Freidlin
1
+ Maximum tolerated dose: clinical endpoint for a bygone era? 2009 Chris H. Takimoto
1
+ Standardversus adaptive monitoring procedures: a commentary 2006 Thomas R. Fleming
1
+ Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method 2014 Nicholas Latimer
Keith R. Abrams
Paul C. Lambert
Michael J. Crowther
Allan Wailoo
J.P. Morden
RL Akehurst
Michael J. Campbell
1
+ Adaptive clinical trials in oncology 2011 Donald A. Berry
1
+ The estimation of average hazard ratios by weighted Cox regression 2009 M. Schemper
Samo Wakounig
Georg Heinze
1
+ A class of rank test procedures for censored survival data 1982 David P. Harrington
Thomas R. Fleming
1
+ Bayesian models for subgroup analysis in clinical trials 2011 Hayley E. Jones
David Ohlssen
Beat Neuenschwander
Amy Racine
Michael Branson
1
+ I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy 2009 AD Barker
C C Sigman
Kelloff Gj
NM Hylton
DA Berry
L. Esserman
1
+ PDF Chat A global logrank test for adaptive treatment strategies based on observational studies 2013 Zhiguo Li
Marcia Valenstein
P. Pfeiffer
Dara Ganoczy
1
+ Cox Regression Methods for Two‐Stage Randomization Designs 2007 Yuliya Lokhnygina
Jeffrey D. Helterbrand
1
+ A statistical model for the dependence between progression‐free survival and overall survival 2009 Frank Fleischer
Birgit Gaschler‐Markefski
Erich Bluhmki
1
+ Randomized Designs for Early Trials of New Cancer Treatments—An Overview 2000 Marc Buyse
1
+ Stopping at Nothing? Some Dilemmas of Data Monitoring in Clinical Trials 2007 Steven N. Goodman
1
+ Bias and Trials Stopped Early for Benefit 2010 Edward L. Korn
1
+ The Role of Statistics in Regulatory Decision Making 2013 Lisa M. LaVange
1
+ Optimising the design of phase II oncology trials: The importance of randomisation 2008 Mark J. Ratain
Daniel J. Sargent
1
+ A Multiple Testing Procedure for Clinical Trials 1979 Peter C. O’Brien
Thomas R. Fleming
1
+ Interim analysis: The alpha spending function approach 1994 David L. DeMets
K. K. Gordon Lan
1
+ PDF Chat A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk 1988 Malcolm H. Ray
1
+ PDF Chat An Audit Strategy for Progression-Free Survival 2011 Lori E. Dodd
Edward L. Korn
Boris Freidlin
Robert J. Gray
Suman Bhattacharya
1
+ Stopping rules and estimation problems in clinical trials 1988 Michael D. Hughes
Stuart J. Pocock
1
+ PDF Chat Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense? 2008 Lori E. Dodd
Edward L. Korn
Boris Freidlin
C. Carl Jaffe
Larry Rubinstein
Janet Dancey
Margaret Mooney
1
+ PDF Chat Blinded Independent Central Review of the Progression-Free Survival Endpoint 2010 Ohad Amit
Will Bushnell
Lori E. Dodd
Nancy Roach
Daniel J. Sargent
1
+ How is retrospective independent review influenced by investigator‐introduced informative censoring: A quantitative approach 2011 Frank Fleischer
Birgit Gaschler‐Markefski
Erich Bluhmki
1
+ PDF Chat In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer 2011 Sunil Verma
Deanna McLeod
Gerald Batist
André Robidoux
Ilidio Martins
John R. Mackey
1
+ Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group 2011 A Stone
William D. Bushnell
Jon Denne
Daniel J. Sargent
Ohad Amit
C. CHEN
R. Bailey-Iacona
Jeffrey D. Helterbrand
Grant Williams
1
+ Conditional Bias of Point Estimates Following a Group Sequential Test 2004 Xiaoyin Fan
David L. DeMets
K. K. Gordon Lan
1